Title:
A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL) View
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Anal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph2 BGB-3111 Ibrut intolerant CLL/SLL View
Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Malignant Adenoma
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 Pembro + BCG High-risk Bladder View
Description: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: IV
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 1/1b TNBC, Ovarian View
Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bone Mets
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Brain Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 Mirv Sora Epi Ova FTC View
Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Penile Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph 1/1b TNBC, Ovarian View
Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Indication:
Breast Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 Mirv Sora Epi Ova FTC View
Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph2 Cervical 2L (RaPiDS) View
Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)
Indication:
Cervical Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Cervical Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph3 TSR-042+car-pac vs plac+car-pac endo View
Description: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) (4010-03-001 / ENGOT EN-6 / GOG-3031)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Biomarker DNA Defect Men Prostate View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Title:
Ph3 Mirv Sora Epi Ova FTC View
Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR PH1b/2 Nirap Combo Tx for mCRPC View
Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Renal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Renal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Sarcoma
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kaposi's Sarcoma
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kidney Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Leukemia
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph2 BGB-3111 Ibrut intolerant CLL/SLL View
Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Liver Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Testicular Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: IV
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Uterine Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vaginal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph2 BGB-3111 Ibrut intolerant CLL/SLL View
Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Malignant Adenoma
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 1/1b TNBC, Ovarian View
Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 Mirv Sora Epi Ova FTC View
Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Penile Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 Mirv Sora Epi Ova FTC View
Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Biomarker DNA Defect Men Prostate View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Title:
STAR PH1b/2 Nirap Combo Tx for mCRPC View
Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Renal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Renal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Sarcoma
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Testicular Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: IV
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Uterine Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vaginal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1/2 MRTX849 Solid Tumors KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II